• Curr Med Res Opin · Feb 2023

    Observational Study

    Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study.

    • Heidi C Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Rentería, A John Rush, Rashmi Patel, Joydeep Sarkar, Heather M Fitzgerald, and Xue Han.
    • Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA.
    • Curr Med Res Opin. 2023 Feb 1; 39 (2): 299306299-306.

    ObjectivesThis observational retrospective real-world study examined changes in healthcare resource utilization (HCRU) pre- and post-initiation of aripiprazole once-monthly (AOM 400) in patients with schizophrenia or bipolar I disorder.MethodsElectronic health record-derived, de-identified data from the NeuroBlu Database (2013-2020) were used to identify patients ≥18 years with schizophrenia (n = 222) or bipolar I disorder (n = 129) who were prescribed AOM 400, and had visit data within 3, 6, 9, or 12 months pre- and post-initial AOM 400 prescription. Rates of inpatient hospitalization, emergency department visits, inpatient readmissions, and average length of stay were examined and compared over 3, 6, 9, and 12 months pre-/post-AOM 400 using a McNemar test.ResultsStatistically significant differences were seen in both schizophrenia and bipolar I disorder patient cohorts pre- and post-AOM 400 in inpatient hospitalization rates (p < .001 all time points, both cohorts) and 30-day readmission per patient rates (p < .001 all time points, both cohorts). Statistically significant improvement in mean length of stay was observed in both cohorts at all time points, except for at six months in patients with schizophrenia. Emergency department visit rates were significantly lower after AOM 400 initiation for both cohorts at all time points (p < .001).ConclusionsA reduction in the rate of hospitalizations, emergency department visits, 30-day readmissions, and average length-of-stay was observed for patients diagnosed with either schizophrenia or bipolar I disorder, which suggests a positive effect of AOM 400 treatment on HCRU outcomes and is supportive of earlier analyses from different data sources.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…